These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28634358)

  • 21. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
    Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
    Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action.
    Wang C; Cheng S; Zhang Y; Ding Y; Chong H; Xing H; Jiang S; Li X; Ma L
    Viruses; 2019 Sep; 11(9):. PubMed ID: 31480738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
    Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
    AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.
    Naito T; Izumi K; Kodama E; Sakagami Y; Kajiwara K; Nishikawa H; Watanabe K; Sarafianos SG; Oishi S; Fujii N; Matsuoka M
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1013-8. PubMed ID: 19114674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.
    Eggink D; Langedijk JP; Bonvin AM; Deng Y; Lu M; Berkhout B; Sanders RW
    J Biol Chem; 2009 Sep; 284(39):26941-50. PubMed ID: 19617355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
    Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
    J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.
    He Y
    Curr Pharm Des; 2013; 19(10):1800-9. PubMed ID: 23092277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
    Eggink D; Baldwin CE; Deng Y; Langedijk JP; Lu M; Sanders RW; Berkhout B
    J Virol; 2008 Jul; 82(13):6678-88. PubMed ID: 18434391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
    Chong H; Yao X; Zhang C; Cai L; Cui S; Wang Y; He Y
    PLoS One; 2012; 7(3):e32599. PubMed ID: 22403678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
    Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K
    Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
    Yi HA; Fochtman BC; Rizzo RC; Jacobs A
    Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
    He Y; Cheng J; Lu H; Li J; Hu J; Qi Z; Liu Z; Jiang S; Dai Q
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16332-7. PubMed ID: 18852475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.